ライフサイエンスコーパス: adenosine A(1) receptor

1 tion than that produced by activation of the adenosine A1 receptor.

2 irments could be ameliorated by blocking the adenosine A1 receptor.

3 a subunits rescued presynaptic inhibition by adenosine A1 receptors.

4 ction by ethanol is mediated through myocyte adenosine A1 receptors.

5 ry effect appears to be due to activation of adenosine A1 receptors.

6 europrotection through activation of central adenosine A1 receptors.

7 more heterogeneous activation of presynaptic adenosine A1 receptors.

8 could transiently be provoked after blocking adenosine A1 receptors.

9 opamine D2, metabotropic glutamate mGlu5 and adenosine A1 receptors.

10 vity for adenosine A(2a) receptor versus the adenosine A(1) receptor.

11 h displayed an affinity of 7 nM on the human adenosine A(1) receptor.

12 neurons in vitro by activating postsynaptic adenosine A(1) receptors.

13 is response is mediated by the activation of adenosine A(1) receptors.

14 r/middle lateral RA had significantly higher adenosine A1 receptor (2.7+/-1.7-fold; P<0.01) and GIRK4

15 tency (hA1, Ki=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A rec

16 Adenosine A(1) receptor (A(1)AR) agonists have antinocic

17 Transient adenosine A(1) receptor (A(1)R) activation in rabbits in

18 t infarction in rabbits 24 to 72 hours after adenosine A(1) receptor (A(1)R) activation.

19 nic pain through sustained activation of the adenosine A(1) receptor (A(1)R) and phospholipase C-medi

20 Activation of adenosine A(1) receptor (A(1)R) by N(6)-cyclopentidylade

21 steric modulators of agonist function at the adenosine A(1) receptor (A(1)R) in two different functio

22 monophosphonate, ACP) directly activated the adenosine A(1) receptor (A(1)R).

23 50% in Nt5e(-/-) mice and were eliminated in Adenosine A(1) receptor (A(1)R, Adora1) knock-out mice.

24 yed preconditioning induced by activation of adenosine A(1) receptors (A(1)ARs) is not fully understo

25 attenuated by activation of either H(3)R or adenosine A(1) receptors (A(1)R).

26 Adenosine A1 receptor (A1-AdoR) function in rat ventricl

27 ic and diuretic action of a highly selective adenosine A1 receptor (A1AdoR) antagonist, 1,3-dipropyl-

28 the hypothesis that a partial agonist of the adenosine A1 receptor (A1AdoR) may cause a greater atten

29 In this study, we targeted the cochlear adenosine A1 receptor (A1AR) by trans-tympanic injection

30 In this study, we show that the adenosine A1 receptor (A1AR) protects against cisplatin

31 Adenosine A1 receptor (A1AR) subtype present on renal pr

32 Allosteric modulation of adenosine A1 receptors (A1ARs) offers a novel therapeuti

33 Neurabin attenuated adenosine A(1) receptor (A1R) signaling by assembling a

34 Adenosine A1 receptor (A1R) agonist N6-cyclopentyl-adeno

35 CPA, a stable adenosine A1 receptor (A1R) agonist, did not affect KDR

36 l blockade of A1 receptor signaling using an adenosine A1 receptor (A1R) antagonist, 8-cyclopentyl-1,

37 ne induces cortical actin polymerization via adenosine A1 receptor (A1R) induction of a Rho GTPase CD

38 The adenosine A1 receptor (A1R) is a key mediator of the neu

39 neuronal activity through activation of the adenosine A1 receptor (A1R), resulting in antinociceptio

40 els around synapses resulting in an enhanced adenosine A1 receptor (A1R)-dependent protective tone de

41 on upregulate adenosine concentration and/or adenosine A1 receptors (A1R) in the brain.

42 This action is shared by adenosine A(1) receptors (A1Rs), which are also located

43 Activation of presynaptic adenosine A1 receptors (A1Rs) causes substantial synapti

44 Adenosine A1 receptors (A1Rs) in human and rodent brains

45 Because very little is known about adenosine A1 receptors (A1Rs) in the spinal cord, we det

46 In hippocampal neurons, activation of adenosine A1 receptors (A1Rs) or GABA(B) receptors on sy

47 seizures in mice by increasing activation of adenosine A1 receptors (A1Rs).

48 ce of heterosynaptic plasticity; blockade of adenosine A1 receptors abolished it.

49 ce of heterosynaptic plasticity: blockade of adenosine A1 receptors abolished weight dependence, whil

50 ective when synaptic activity was reduced by adenosine A(1) receptor activation, and a combination of

51 Adenosine A1 receptor activation also impaired the expre

52 algesic effect of acupuncture is mediated by adenosine A1 receptor activation at the acupuncture poin

53 The inhibitory modulation of adenosine A1 receptor activation by hydroxylamine sugges

54 Adenosine A1 receptor activation depresses excitatory tr

55 Adenosine A1 receptor activation dose-dependently and se

56 P inhibited excitatory neurotransmission via adenosine A1 receptor activation in spinal cord slices f

57 this model of trigeminovascular nociception, adenosine A1 receptor activation leads to neuronal inhib

58 een reported in response to agonist-mediated adenosine A1 receptor activation, the implications of A2

59 is study, we report a novel dual role of the adenosine A1 receptor (Adora1) as an E2/ERalpha target a

60 ssion of a potential glucagon inhibitor, the adenosine A1 receptor (Adora1), is gradually diminished

61 sponses are thought to require activation of adenosine A1 receptors (adorA1Rs) and release of transmi

62 However, incubation with the adenosine A(1) receptor agonist 2-chlorocyclopentyladeno

63 ecular meshwork cells to the addition of the adenosine A(1) receptor agonist N(6)-cyclohexyladenosine

64 The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine

65 to adenosine, N(6)-cyclopentyladenosine (an adenosine A(1) receptor agonist), and 2-[p-(2-carboxyeth

66 extent as ischemic preconditioning, but the adenosine A(1) receptor agonist, 2-chloro-N(6)-cyclopent

67 -D-aspartate receptor antagonist MK-801; the adenosine A1 receptor agonist 2-chloro-N6-cyclopentylade

68 the GABA(B) receptor agonist baclofen or the adenosine A1 receptor agonist 2-chloroadenosine, short-t

69 These data are consistent with adenosine A1 receptor agonist actions on REM sleep media

70 the NO donor sodium nitroprusside (SNP), the adenosine A1 receptor agonist CCPA (2-chloro-N6-cyclopen

71 osine A2a receptor agonist APEC, but not the adenosine A1 receptor agonist CHA, attenuated c-Fos indu

72 Intrastriatal microinfusion of adenosine A1 receptor agonist N6-cyclohexyladenosine (CH

73 Pretreatment with the adenosine A1 receptor agonist N6-cyclohexyladenosine (CH

74 of the BF cholinergic neurons, the selective adenosine A1 receptor agonist N6-cyclohexyladenosine, ad

75 ditioning was mimicked by perfusion with the adenosine A1 receptor agonist N6-cyclopentyladenosine an

76 Microinjection of adenosine A1 receptor agonist or an inhibitor of adenyly

77 Direct injection of an adenosine A1 receptor agonist replicated the analgesic e

78 lisopropyl)-adenosine (R-PIA [50 nmol/L], an adenosine A1 receptor agonist), or 4 beta-phorbol 12-myr

79 The selective low efficacy adenosine A1 receptor agonist, GR190178 (30-1000 microg/

80 enous administration of the highly selective adenosine A1 receptor agonist, GR79236 (3-100 microg/kg)

81 N6-Cyclopentyl adenosine (adenosine A1 receptor agonist, Kd = 1 nmol/l) did not af

82 Systemic injection of the selective adenosine A1 receptor agonist, N(6)-cyclohexyladenosine

83 lure was studied with the use of a selective adenosine A1 receptor agonist, N6-cyclohexyl-2'-O-methyl

84 In Experiment 1, the selective adenosine A1 receptor agonist, N6-cyclopentyladenosine (

85 A, 48.4+/-5.5% with SfA; P<0.001), CCPA (the adenosine A1-receptor agonist, 200 nmol/L) (24.9+/-4.5%

86 the effects of capadenoson (CAP), a partial adenosine A1-receptor agonist, on left ventricular (LV)

87 The selective adenosine A1 receptor agonists 2-chloro-N6-cyclopentylad

88 flammatory sites was signficantly reduced by adenosine A1 receptor agonists injected through intrathe

89 is a considerable literature to suggest that adenosine A1 receptor agonists may have anti-nociceptive

90 onists, nitric oxide synthase inhibitors and adenosine A1 receptor agonists.

91 The results support development of partial adenosine A1-receptor agonists for the treatment of chro

92 Therapy with adenosine A1-receptor agonists, however, is limited by u

93 Overexpressing the adenosine A1 receptor also led to increased protection a

94 Allosteric enhancers of the adenosine A1 receptor amplify signaling by orthosteric a

95 To confirm the involvement of adenosine A(1) receptors and matrix metalloproteinases (

96 amine D2 receptor, dopamine transporter, and adenosine A1 receptor and decreased adenosine A2A recept

97 al inhibition was blocked in the presence of adenosine A1 receptor and GABAB receptor blockade.

98 entry in RA areas with highest expression of adenosine A1 receptor and its downstream GIRK (G protein

99 denosine (2CA) and baclofen, agonists of the adenosine A1 receptor and the GABAB receptor, respective

100 previously produced up-regulation of central adenosine A1 receptors and created a state of opiate dep

101 e examined the manner in which activation of adenosine A1 receptors and GABAB receptors modulates syn

102 Given the similar involvement of NMDARs, adenosine A(1) receptors, and PP1 in depotentiation of L

103 ynthesis, which was prevented by blockade of adenosine A1 receptors, and decreased expression of gene

104 f ATP-sensitive potassium (K(ATP)) channels, adenosine A1 receptors, and the effects of different lev

105 attenuated by adrenergic alpha 2-receptors, adenosine A1-receptors, and histamine H3-receptors.

106 Moreover, adenosine A1 receptor antagonism had larger effects on t

107 s to cardiac arrhythmias and seizures due to adenosine A1-receptor antagonism.

108 enhanced pLTF (85 +/- 11%, P < 0.05), but an adenosine A(1) receptor antagonist (DPCPX, 3 microg kg(-

109 uced secretion of MMP-2 was inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dim

110 responses were not altered by the selective adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dip

111 ontrol hypoxic response, is inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dip

112 The adenosine A(1) receptor antagonist 8-cyclopentyltheophyl

113 Pretreatment with the adenosine A(1) receptor antagonist CPT (10 microM) or th

114 were also quantified after microinjecting an adenosine A(1) receptor antagonist into the prefrontal c

115 cerebrospinal fluid (aCSF) and two doses of adenosine A(1) receptor antagonist, 1,3-dipropyl-8-pheny

116 e evaluated in preparations treated with the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-di

117 membrane, an effect that was blocked by the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-di

118 BTI), or exogenous adenosine, or a selective adenosine A1 receptor antagonist (8-cyclopentyl-1, 3-dim

119 The adenosine A1 receptor antagonist 1,3-dipopylcyclopentylx

120 (19.6 +/- 0.9%) by systemic injection of the adenosine A1 receptor antagonist 8-CPT (2.5 mg kg(-1)) a

121 was largely reversed in the presence of the adenosine A1 receptor antagonist 8-cyclopentyl-1, 3-dipr

122 Both the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

123 (NOS) inhibitor l-NAME (Group 1, n = 8) and adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

124 The adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

125 denosine as a mediator of IPC, the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

126 The selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

127 roduced by the administration of a selective adenosine A1 receptor antagonist but not by a selective

128 Prior administration of the selective adenosine A1 receptor antagonist dipropylcyclopentylxant

129 GR79236 could be inhibited by the selective adenosine A1 receptor antagonist DPCPX (300 microg/kg; P

130 fore and after administration of a selective adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,

131 value of 0.4 nM for antagonism of CPA by the adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,

132 The adenosine A1 receptor antagonist DPCPX did not affect th

133 Intracerebroventricular infusion of an adenosine A1 receptor antagonist produced a similar decr

134 Here, we show that the adenosine A1 receptor antagonist rolofylline (KW-3902) i

135 Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patient

136 is comparable to that of BG9928, a selective adenosine A1 receptor antagonist that is currently in cl

137 yl-1,3-dipropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist that is permeable to th

138 Imidazoline 14 is a competitive adenosine A1 receptor antagonist with a pA2 value of 8.8

139 -i]purin-5(4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity o

140 In the search for a selective adenosine A1 receptor antagonist with greater aqueous so

141 e presence of SPWs in slices treated with an adenosine A1 receptor antagonist, a finding that links t

142 blocked by protein kinase A inhibitor and an adenosine A1 receptor antagonist.

143 ices treated with either a glial toxin or an adenosine A1 receptor antagonist.

144 s with ADHF and volume overload, KW-3902, an adenosine A1-receptor antagonist, enhances the response

145 e hypothesis that the use of rolofylline, an adenosine A1-receptor antagonist, would improve dyspnea,

146 Adenosine A(1) receptor antagonists have been used effec

147 fibrillation were abolished or prevented by adenosine A1 receptor antagonists (50 mumol/L theophylli

148 The inhibition was blocked by adenosine A1 receptor antagonists and by agents that dis

149 vel tricyclic imidazoline antagonists of the adenosine A1 receptor are described.

150 cardial ischemia-reperfusion injury and that adenosine A1 receptors are required for this protective

151 These results indicate that adenosine A1 receptors are selectively upregulated durin

152 tion and increased neuronal excitability via adenosine A(1) receptors, ATP receptors, and ecto-ATPase

153 By contrast, adenosine A(1) receptor blockade did not prevent protect

154 ing new treatments, we studied the effect of adenosine A(1) receptor blockade or deletion on bone den

155 Adenosine A1 receptor blockade abolished the protection

156 67156) inhibition of nucleotide breakdown or adenosine A1 receptor blockade and reduced by apyrase in

157 Adenosine A1 receptor blockade with 4.5 mg/kg DPCPX admi

158 ht to evaluate the dose-dependent effects of adenosine A1-receptor blockade on diuresis and renal fun

159 yclopentyl-1, 3-dipropylxanthine (DPCPX) (an adenosine A1 receptor blocker).

160 manipulated by microperfusing nephrons with adenosine A1 receptor blocker, A1-agonist, or 5'-nucleot

161 gated by TRPV4 channel, GABAB, as well as an adenosine A1 receptor blocker.

162 rent and GIRK channel activation mediated by adenosine A(1) receptors, but not GABA(B) receptors.

163 iated by increased activation of presynaptic adenosine A1 receptors by endogenous adenosine.

164 Adenosine A1 receptor control of the homeostatic regulat

165 antisense oligodeoxynucleotide targeting the adenosine A1 receptor desensitized the animals to subseq

166 haracterize SAN structure, SAN function, and adenosine A1 receptor expression in control (n=17) and 4

167 ption of caffeine during adulthood increased adenosine A1 receptor expression in the NAc, but no othe

168 d that its anti-nociceptive actions required adenosine A1 receptor expression.

169 were conducted to examine the importance of adenosine A1 receptors for the acquisition and expressio

170 chemia might be attributable to the enhanced adenosine A1 receptor function on synaptic transmission,

171 ibitory G-protein-coupled receptors (GPCRs) (adenosine A(1) receptors, GABA(B) receptors, metabotropi

172 lized in lateral RA regions with the highest adenosine A1 receptor/GIRK4 expression.

173 To inhibit K(ATP) channels or adenosine A1 receptors, glibenclamide (0.1 mg/kg icv; n

174 5-cyano-2-thiopyrimidines as selective human adenosine A1 receptor (hA1AR) agonists with tunable bind

175 tively attenuates discordantly overexpressed adenosine A(1) receptors in allergic lung.

176 ide evidence for the existence of functional adenosine A(1) receptors in the trabecular cells and tha

177 ffects, and we sought to explore the role of adenosine A1 receptors in a model of trigeminovascular n

178 Stimulation of renal adenosine A1 receptors in animal models has resulted in

179 blood brain barrier, we examine the role of adenosine A1 receptors in mediating cortical blood flow

180 d by endogenous GABAB, serotonin 5-HT1A, and adenosine A1 receptors in neurons coinfected with GIRK1+

181 In vitro studies supported roles for adenosine A1 receptors in promoting fatty acid synthesis

182 ncreases the concentrations of adenosine and adenosine A1 receptors in specific regions of the brain.

183 al (AAV) vector to focally delete endogenous adenosine A1 receptors in the hippocampus.

184 alothane level but not of K(ATP) channels or adenosine A1 receptors in the preconditioning effects of

185 entylxanthine, indicating the involvement of adenosine A1 receptors in the protection.

186 gical evidence supporting the involvement of adenosine A1 receptors in the regulation of the response

187 response (HVR), and investigated the role of adenosine A1 receptors in these SF effects in conscious

188 This effect requires functional adenosine A1 receptors, in line with the observation tha

189 ition, the role of adenosine--acting through adenosine A(1) receptors--in renal autoregulation has be

190 ptor antagonists and completely abolished by adenosine A(1) receptor inhibition.

191 (l-NAME, 1.5 mM), but was not affected by an adenosine A1 receptor inhibitor, 8-cyclopentyl-1,3-dipro

192 While activation of inhibitory adenosine A(1) receptors is beneficial in epilepsy, chro

193 e first time in the mammalian fetus that the adenosine A1 receptor is an important mediator of brain

194 uction or oxygen consumption, suggesting the adenosine A1 receptor is involved in lowering metabolic

195 t-limiting protection of PostC was absent in adenosine A(1) receptor knockout mice (34.9+/-2.7%) or b

196 The bone mineral density (BMD) in adenosine A(1) receptor-knockout (A(1)R-knockout) mice w

197 Studies have shown that the activation of adenosine A(1) receptors lower intraocular pressure prim

198 Furthermore, activation of adenosine A1-receptors markedly attenuated norepinephrin

199 These results suggest that the adenosine A(1) receptor may be a useful target in treati

200 xperiments, hydroxylamine did not affect the adenosine A(1) receptor-mediated depression of postsynap

201 ydroxylamine acts presynaptically to counter adenosine A(1) receptor-mediated inhibition of synaptic

202 veal a novel role for the PP2A holoenzyme in adenosine A(1) receptor-mediated regulation of NHE1 acti

203 l natriuretic peptide level, consistent with adenosine A1 receptor-mediated activity, was observed.

204 A3 receptors with Cl-IB-MECA antagonized the adenosine A1 receptor-mediated inhibition of excitatory

205 These data provide good evidence for an adenosine A1 receptor-mediated inhibition of mAChR-media

206 GABA does not appear to be involved in adenosine A1 receptor-mediated inhibition of neuronal fi

207 In addition, hydroxylamine reversed adenosine A1 receptor-mediated inhibition of the evoked

208 Agents that inhibit adenosine A1 receptors might be useful in the treatment

209 Adenosine A1 receptors modulate baseline synaptic transm

210 or agonists directly reduces tremor, whereas adenosine A1 receptor-null mice show involuntary movemen

211 A presynaptic site of action for adenosine A(1) receptors on glutamatergic afferents was

212 nd Western analysis revealed the presence of adenosine A(1) receptors on trigeminal neurons.

213 Activation of either adenosine A1 receptors or GABAB receptors inhibits many

214 lly, we show that blocking the activation of adenosine A1 receptors prevents the long-term depression

215 This study revealed a 3-fold RA-to-LA adenosine A1 receptor protein expression gradient in the

216 Adenosine A1 receptor protein expression was significant

217 had no effect, but those for adrenergic and adenosine A1 receptors reduced firing.

218 er, our data indicate that activation of the adenosine A1 receptor reduces synaptic strength by modul

219 Upon solubilization, the retinal adenosine A1 receptor retained binding characteristics s

220 yl-1,3-dipropylxanthine (DPCPX) (100 ng), an adenosine A(1) receptor selective antagonist, completely

221 be potently and effectively inhibited by the adenosine A(1) receptor-selective agonist GR79236X (pIC(

222 -induced motor incoordination in mice by the adenosine A(1) receptor-selective agonist N(6)-cyclohexy

223 at caffeine, because of its ability to block adenosine A1 receptors, shares neurochemical properties

224 mals received intravitreal injections of the adenosine A1 receptor stimulant adenosine amine congener

225 Adenosine A(1) receptor stimulation inhibits this respon

226 osine mediates neuroprotection by activating adenosine A(1) receptor subtype (A(1)AR) linked to suppr

227 The selectivity level over the adenosine A1 receptor subtype for some of the more activ

228 to be mediated by a pathway initiated at the adenosine A1 receptor that transduced signals through a

229 uction in IOP results from the activation of adenosine A1 receptors, the mechanisms responsible for t

230 sites flanking the major coding exon for the adenosine A1 receptor, this AAV-Cre markedly reduced A1

231 In chronic HF, adenosine A1 receptor upregulation in SAN pacemaker and

232 tivation of a postsynaptic K+ conductance by adenosine A1 receptors was used to determine the rate of

233 t cardiac ventricular myocytes, 67 +/- 5% of adenosine A(1) receptors were isolated with caveolae.

234 for GABA(B) receptors, 5HT1A receptors, and adenosine A1 receptors were essentially absent in mutant

235 As an example we show that the adenosine A1 receptor, when placed under the influence o

236 Activation of the adenosine A1 receptor with CCPA or the A3 receptor with

237 The results provide novel evidence that adenosine A(1) receptors within the prefrontal cortex co

238 In this study, we tested the hypothesis that adenosine A(1) receptors would translocate to caveolae i